Grenis-Cipro (Ciprofloxacin Hydrochloride)

Grenis-Cipro is indicated for the treatment of several types of bacterial infections where ciprofloxacin is appropriate. It is commonly prescribed for:

• Uncomplicated urinary tract infections caused by susceptible organisms.
• Acute respiratory tract infections, including bronchitis and sinusitis.
• Skin and soft tissue infections such as cellulitis and wound infections.
• Gastrointestinal infections like traveler's diarrhea and bacterial dysentery.
• Infections where alternative agents are not suitable or have failed.

Side effects of Grenis-Cipro vary in frequency and severity. Patients should be aware of both common and serious reactions.

Common

• Nausea or vomiting
• Diarrhea, which may be mild to moderate
• Headache
• Dizziness or light‑headedness
• Abdominal discomfort or pain
• Rash or mild skin irritation

Serious

• Tendon rupture or inflammation, especially in the Achilles tendon
• Peripheral neuropathy presenting as tingling or numbness
• Severe allergic reactions, including anaphylaxis
• Clostridioides difficile‑associated colitis
• QT interval prolongation leading to cardiac arrhythmias
• Significant elevation of liver enzymes or hepatic injury

Before starting Grenis-Cipro, certain precautions should be considered to minimize risks. Important points include:

• Known hypersensitivity to ciprofloxacin, other fluoroquinolones, or any component of the formulation.
• Use with caution in patients with renal impairment; dosage adjustment may be required.
• Pregnancy and lactation status are not well established; avoid unless clearly needed.
• Concomitant corticosteroid therapy increases the risk of tendon injury.
• Potential for photosensitivity; advise protection from excessive sunlight.
• Patients with a history of seizures or CNS disorders should be monitored closely.
• Evaluate for QT‑prolonging risk factors before prescribing.

Grenis-Cipro can interact with several medicines, affecting its efficacy or safety. Interactions are grouped by recommended action.

Avoid

• Antacids containing magnesium or aluminum, sucralfate, and iron supplements (reduce absorption).
• Warfarin (may increase INR and bleeding risk).
• Theophylline (increased plasma concentrations).
• Cyclosporine (higher levels may lead to toxicity).

Use with caution

• Non‑steroidal anti‑inflammatory drugs (enhanced CNS side effects).
• Systemic corticosteroids (greater tendon‑rupture risk).
• Oral contraceptives (possible reduction in effectiveness).
• Other QT‑prolonging agents (additive cardiac risk).
• Diabetes medications (potential alterations in blood glucose control).